Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This study observed that a combination of two mineral and nutritional supplement products increased anagen-phase hair and reduced hair loss in women with androgenetic alopecia and acute or chronic telogen effluvium after four months.

This study reviewed various studies and concluded that Janus kinase inhibitors, particularly tofacitinib, seem to promote hair regrowth in about half of patients with alopecia areata, though expected class-specific adverse effects were observed.